EP Patent

EP3297631A1 — Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases

Assigned to Nerre Therapeutics Ltd · Expires 2018-03-28 · 8y expired

What this patent protects

This invention relates to new use of dual NK-1/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof in the treatment of sex-hormone dependent diseases.

USPTO Abstract

This invention relates to new use of dual NK-1/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof in the treatment of sex-hormone dependent diseases.

Drugs covered by this patent

Patent Metadata

Patent number
EP3297631A1
Jurisdiction
EP
Classification
—
Expires
2018-03-28
Drug substance claim
No
Drug product claim
No
Assignee
Nerre Therapeutics Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.